Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells

被引:9
|
作者
Olatunji, Feyisola P. [1 ]
Savoy, Emily A. [1 ]
Panteah, Mylan [2 ]
Mesbahi, Nooshin [1 ]
Abbasi, Armina [1 ]
Talley, Cresencia M. [1 ]
Lovingier, Christine L. [1 ]
Caromile, Leslie A. [2 ]
Berkman, Clifford E. [1 ]
机构
[1] Washington State Univ, Dept Chem, Pullman, WA 99164 USA
[2] UCONN Hlth Ctr Vasc Biol, Farmington, CT 06030 USA
基金
美国国家卫生研究院;
关键词
MONOCLONAL-ANTIBODY; FOLATE HYDROLASE; TUMOR-CELLS; PH; INHIBITOR; PSMA; PET; INTERNALIZATION; THERAPY; APTAMER;
D O I
10.1021/acs.bioconjchem.1c00435
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered controlled-release platforms, particularly in the context of antibody-and small-molecule-drug conjugates (ADCs and SMDCs), where there remains a need for new linker technology. Herein, we explored in-depth the release of turn-on fluorogenic payloads from a homoserinyl-based phosphoramidate acid-cleavable linker. Kinetics of payload release from the scaffold was observed in buffers representing the pH conditions of systemic circulation, early and late endosomes, and lysosomes. It was found that payload release takes place in two key consecutive steps: (1) P-N bond hydrolysis and (2) spacer immolation. These two steps were found to follow pseudo-first-order kinetics and had opposite dependencies on pH. P-N bond hydrolysis increased with decreasing pH, while spacer immolation was most rapid at physiological pH. Despite the contrasting release kinetics of these two steps, maximal payload release was observed at the mildly acidic pH (5.0-5.5), while minimal payload release occurred at physiological pH. We integrated this phosphoramidate-payload linker system into a PSMA-targeted fluorescent turn-on probe to study the intracellular trafficking and release of a fluorescent payload in PSMA-expressing prostate cancer cells. Results showed excellent turn-on and accumulation of the coumarin payload in the late endosomal and lysosomal compartments of these cells. The release properties of this linker mark it as an attractive alternative in the modular design of ADCs and SMDCs, which demand selective intracellular payload release triggered by the pH changes that accompany intracellular trafficking.
引用
收藏
页码:2386 / 2396
页数:11
相关论文
共 50 条
  • [1] Prostate-specific membrane antigen-targeted imaging, diagnosis, and therapy of prostate cancer
    Kularatne, Sumith A.
    Low, Philip S.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [2] Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo
    Zhang, Haichong K.
    Chen, Ying
    Kang, Jeeun
    Lisok, Ala
    Minn, Il
    Pomper, Martin G.
    Boctor, Emad M.
    JOURNAL OF BIOPHOTONICS, 2018, 11 (09)
  • [3] Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer
    Lawal, Ismaheel O.
    Bruchertseifer, Frank
    Vorster, Mariza
    Morgenstern, Alfred
    Sathekge, Mike M.
    CURRENT OPINION IN UROLOGY, 2020, 30 (01) : 98 - 105
  • [4] Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostics for Prostate Cancer
    Solanki, Krishna
    Ahmed, Nazeer
    Srivastava, Nidhi
    Meher, Niranjan
    ACS APPLIED BIO MATERIALS, 2024, 7 (09): : 5861 - 5884
  • [5] Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
    Rowe, Steven P.
    Drzezga, Alexander
    Neumaier, Bernd
    Dietlein, Markus
    Gorin, Michael A.
    Zalutsky, Michael R.
    Pomper, Martin G.
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 : 90S - 96S
  • [6] Targeted PET imaging for prostate-specific membrane antigen in prostate cancer
    Hope, Thomas A.
    Aggarwal, Rahul R.
    Westphalen, Antonio C.
    Cooperberg, Matthew R.
    Greene, Kirsten L.
    FUTURE ONCOLOGY, 2016, 12 (21) : 2393 - 2396
  • [7] Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
    Corpetti, Matteo
    Mueller, Cristina
    Beltran, Himisha
    de Bono, Johann
    Theurillat, Jean-Philippe
    EUROPEAN UROLOGY, 2024, 85 (03) : 193 - 204
  • [8] Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer
    Yamamichi, Gaku
    Kato, Taigo
    Watabe, Tadashi
    Hatano, Koji
    Uemura, Motohide
    Nonomura, Norio
    ANTICANCER RESEARCH, 2024, 44 (03) : 879 - 888
  • [9] First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright
    Lamb, Alastair D.
    Bryant, Richard J.
    Mills, Ian G.
    Hamdy, Freddie C.
    EUROPEAN UROLOGY, 2018, 73 (05) : 653 - 655
  • [10] Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates
    Nakajima, Ryo
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2024, 72 (02) : 136 - 142